In a report published Monday, Barrington Research reiterated its Outperform rating on SurModics SRDX and raised its price target from $18.00 to $20.00.
Barrington noted, “We are maintaining our OUTPERFORM rating and raising our target from $18 to $20 as we believe SRDX's improving fundamentals and recently-announced $50 million share repurchase program have significantly increased our outlook regarding the future. Our rating is based on the belief that SRDX will maintain high market share in a drug/device convergence market that will likely increase several-fold over the next decade. We are impressed with SRDX's financial and non-financial improvements and we have increasing confidence in this new management team.”
SurModics closed on Friday at $17.57.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in